Trials / Completed
CompletedNCT00331500
Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis
A Comparative Study of Olopatadine 0.2% Versus Vehicle in Patients With Seasonal Allergic Conjunctivitis or Rhinoconjunctivitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 287 (actual)
- Sponsor
- Alcon Research · Industry
- Sex
- All
- Age
- 10 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to demonstrate that Olopatadine 0.2% is superior to vehicle in the treatment of the signs and symptoms associated with allergic conjunctivitis or rhinoconjunctivitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olopatadine Hydrochloride Ophthalmic Solution, 0.2% | |
| DRUG | Olopatadine Hydrochloride Ophthalmic Solution Vehicle | Inactive ingredients used as a placebo comparator |
Timeline
- Start date
- 2006-04-18
- Primary completion
- 2006-07-27
- Completion
- 2006-07-27
- First posted
- 2006-05-31
- Last updated
- 2017-08-14
Source: ClinicalTrials.gov record NCT00331500. Inclusion in this directory is not an endorsement.